🔬 Founding Member Rate: $4.99/mo — locks in forever.
Price doubles to $9.99 on July 10.
Lock it in →
What Is It?
Five compounds researched for weight management, each targeting a different mechanism. Some suppress appetite. Some target fat directly. Some mimic exercise.
Compounds Covered
- Semaglutide — GLP-1 agonist. Recalibrates the hunger thermostat. ~15% weight loss. FDA-approved (Ozempic/Wegovy).
- Tirzepatide — Dual GLP-1/GIP agonist. Turns down two dials. ~22% weight loss. FDA-approved (Mounjaro/Zepbound).
- Retatrutide — Triple GLP-1/GIP/glucagon agonist. Three dials. ~28.7% weight loss. Phase 3, not yet approved.
- AOD-9604 — HGH fragment 176-191. Targets fat oxidation only, no appetite suppression. Trials failed at scale.
- MOTS-c — Mitochondrial exercise mimetic. Metabolic enhancement. Mouse data only for exogenous use.
Run the Numbers
Compare reconstitution math across weight-loss peptides — BAC water volume, syringe units, weekly totals. Free, no login required.
Open the Calculator →The Honest Part
- Only Semaglutide and Tirzepatide are FDA-approved, and they require a prescription.
- AOD-9604 trials failed — the compound didn't beat diet and exercise in larger studies.
- MOTS-c has no human trial data for weight loss.
- FDA has warned about counterfeit GLP-1 vendors.
- This is education, not a prescription.
- For research purposes only.
Research Sources
Verified vendors offering this compound for research purposes. Use code ROCN10 for discounts. We may earn commissions from these links.
Track Weight Loss Peptides in the App
Peptide Manager Pro tracks 100+ compounds with an interactive knowledge graph, dosing calculator, protocol tracker, and AI research chat. Veteran-owned. $4.99/mo founding rate.
Get the App →